Apo-Clozapine (clozapine) is an atypical antipsychotic drug indicated for the management of symptoms in treatment-resistant schizophrenia. Due to the risk of agranulocytosis (the lowering of white blood cells) with the use of clozapine, the Apo-Clozapine Risk Management Program was created to ensure optimal safety for all patients receiving Apo-Clozapine.